This is an international, multicenter, open-label, randomized, Phase 3 study in patients with locally advanced, inoperable, or metastatic triple-negative breast cancer (mTNBC) who have not received previous therapy for advanced disease and whose tumors are PD-L1 positive (defined using the PD-L1 IHC 22C3 assay as tumors with a combined positive score [CPS] ≥ 10) at screening.

This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of Pembrolizumab. This study will also assess the clinical benefit of combination therapy in participants with advanced unresectable and/or metastatic ICI refractory solid tumors OR ICI naïve MSS/MSI-low solid tumors

This is a translational clinical study aiming to develop approaches to process effectively human tissues and identify biomarkers for painful and non-painful chemotherapy-induced peripheral neuropathy (CIPN). This study will involve obtaining two skin biopsies representing affected and non-affected parts of each patient’s limb. Painful and non-painful neuropathies will be determined by a variety of standard approaches implemented by a neurologist Dr. Bhavaraju-Sanka.  

The goal of this study is to learn if circulating tumor DNA and other tumor-related molecules/chemicals released in the blood can help doctors predict if colorectal cancer may come back or spread.

This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth

Are you undergoing treatment for a blood cancer diagnosis and experiencing poor sleep?Researchers at the Mays Cancer Center are seeking US-based adults diagnosed with blood cancer and experiencing sleep disturbance to participate in a 20-week remote study testing a digital wellness intervention. Participants in this study will be assigned to use one of two digital wellness apps 10 minutes per day over 8-weeks to determine if it can help improve sleep, immune function, and other psychological and emotional outcomes.This study is completely remote (there are no in-person visits with the research team) and patients from across the USA are invited.Participation involves:One brief 30-minute virtual meeting with a research assistantCompleting online surveysProviding three blood samples over the 20-week study at a lab close to youTracking sleep using a small device and daily diaryUsing a wellness app for 10 minutes per day for 8-weeksParticipants who qualify and are enrolled in the study will be compensated at regular intervals, up to $100 total.

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.